GlassScriptPhysician profile
Trevor Glanville
NPI 1326703091
$12,526.84
in general payments reported to CMS, 2019-2025
29 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.43 · 2022: $5,518 · 2023: $3,866 · 2024: $2,640 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,934 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,934.17 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,406.93 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Inceptiv |
| Mml US, INC. | $1,674.09 | 2022-2025 | Reactiv8 |
| Boston Scientific Corporation | $1,507.79 | 2022-2024 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $942.22 | 2022-2024 | Relistor |
| Abbvie INC. | $750.92 | 2022-2024 | |
| Collegium Pharmaceutical, INC. | $745.16 | 2022-2024 | Xtampza |
| Kowa Pharmaceuticals America, INC. | $393.82 | 2022-2023 | Seglentis |
| Pfizer INC. | $282.39 | 2023-2024 | |
| Relievant Medsystems, INC. | $226.75 | 2023 | Intracept |
| Tersera Therapeutics LLC | $188.39 | 2022-2024 | Prialt |
| Horizon Therapeutics Plc | $149.79 | 2022 | |
| Depuy Synthes Sales INC. | $149.46 | 2025 | Teligen |
| Merz Pharmaceuticals, LLC | $145.25 | 2023-2024 | Xeomin |
| Scilex Pharmaceuticals INC. | $128.33 | 2022-2023 | Ztlido |
| Augmedics INC. | $126.29 | 2024 | Xvision |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Forte Bio-Pharma LLC | $124.06 | 2023-2024 | Prolate, Nalocet |
| Biohaven Pharmaceutical Holding Company LTD. | $106.84 | 2022 | |
| Almatica Pharma LLC | $87.77 | 2021-2022 | |
| Protega Pharmaceutials INC | $65.10 | 2024 | Roxybond |
| Amneal Pharmaceuticals LLC | $55.21 | 2022 | |
| Cerapedics INC. | $44.80 | 2025 | I-Factor Peptide Enhanced Bone Graft |
| Allergan, INC. | $41.45 | 2022 | |
| Hikma Pharmaceuticals USA | $40.16 | 2022 | |
| Grt US Holding, INC. | $37.90 | 2021-2022 | |
| Si-Bone, INC. | $24.23 | 2024 | |
| Fidia Pharma USA INC. | $22.45 | 2022 | |
| Stryker Corporation | $22.27 | 2025 | Mako |
| Teva Pharmaceuticals USA, INC. | $18.57 | 2022 | |
| Medline Industries LP | $18.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trevor Glanville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.